Kapil Dhingra

Founder at Kapital Consulting LLC

Kapil Dhingra

Kapil Dhingra

Founder at Kapital Consulting LLC

Overview
Career Highlights

Kapital Consulting LLC

RelSci Relationships

1488

Number of Boards

28

Birthday

1960

Age

61

Relationships
RelSci Relationships are individuals Kapil Dhingra likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Autolus Therapeutics Plc

Relationship likelihood: Strong

Former Executive Deputy Chairman at Oxxon Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Omega Fund Management LLC

Relationship likelihood: Strong

Co-Founder at Replimune Group, Inc.

Relationship likelihood: Strong

Founder at Replimune Group, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at Five Prime Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Forbion Capital Partners Management Holding BV

Relationship likelihood: Strong

Partner at Sofinnova Partners SAS

Relationship likelihood: Strong

Former Executive Vice President & Chief Financial Officer at TransEnterix, Inc.

Relationship likelihood: Strong

Former Chief Scientific Officer at Chiron Corp.

Relationship likelihood: Strong

Paths to Kapil Dhingra
Potential Connections via
Relationship Science
You
Kapil Dhingra
Founder at Kapital Consulting LLC
Education
Career History
Founder
2008 - Current
Current

Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Saint Genis Pouilly, France.

Tenure Unconfirmed

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. Its product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Boards & Committees
Member, Oncology Scientific Advisory Board
2016 - Current

Asana BioSciences LLC, a subsidiary of Amneal Pharmaceuticals, Inc., is an American company located in Lawrenceville, NJ. The firm operates as a clinical-stage biopharmaceutical company. It was founded by Chintu Patel.The company says this about itself: Asana BioSciences is a clinical stage biopharmaceutical company based in Lawrenceville, NJ. Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology. ASN003 is in Phase 1 development for BRAFV600 mutated metastatic melanoma, metastatic colorectal and advanced non-small cell lung cancer, and advanced solid tumors with PI3K pathway alterations (NCT02961283). ASN004 is an antibody drug conjugate that targets the 5T4 oncofetal antigen, which is expressed in a wide range of malignant tumors but has very limited expression in normal tissues. ASN004 demonstrates robust and durable antitumor activity after single administration in multiple human tumor xenograft models. ASN008 is a novel, topical Na+-channel blocker with high functional selectivity for itch and pain sensing neurons without affecting motor neurons. In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief after a single application, which lasted between 8-12 hours, and no tachyphylaxis to this response was observed after 2 weeks of daily application (NCT03798561).

Member, Clinical Advisory Board
Current

Oncos Therapeutics Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Independent Director
2012 - 2013

YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kapil Dhingra. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kapil Dhingra's profile does not indicate a business or promotional relationship of any kind between RelSci and Kapil Dhingra.